Dr. Steven J. Nurkin, MD

Dr. Nurkin practices at Roswell Park Cancer Institute in Los Angeles, California.

Dr. Nurkin's NPI, 1639323850, was assigned on November 14, 2008. Dr. Nurkin graduated from Technion-Israel Inst of Technology Faculty of Medicine in 2005. Dr. Nurkin holds New York license 256933.

Dr. Nurkin's primary practice is Roswell Park Cancer Institute, at 344 S Hauser Blvd, Los Angeles, CA 90036 in Los Angeles County. The practice phone is (716) 845-2300.

Dr. Nurkin's primary practice is Roswell Park Cancer Institute in Los Angeles, California. Dr. Nurkin is also affiliated with Roswell Park Comprehensive Cancer Center. The medical group on file is Roswell Park Comprehensive Cancer Center. Dmand AI also links Dr. Nurkin to 1 more home health agency, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Nurkin practices, 2 sites in all. Vendor and product names are available with a free account.

Surgical oncology is Dr. Nurkin's primary specialty in the NPI Registry, under taxonomy code 2086X0206X. Dr. Nurkin is licensed in New York.

CMS data shows 14 Medicare services from Dr. Nurkin across 1 procedure code in 2024, all of them office visits, for 51 Medicare patients. Medicare paid $1,459 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 51 Medicare patients who saw Dr. Nurkin in 2024. The largest group is 65 to 74, with 24 patients. 75% of them have cancer, and 75% have high cholesterol. 24% are also on Medicaid. Their average risk score is 2.16, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Nurkin's median patient age at 70, with 42% women.

In 2018, Dr. Nurkin wrote 14 Medicare Part D claims. Every claim was for a generic drug. They cover 1 drug, with $37 in total drug cost. In 2017, CMS named 12 claims across 1 drug.

Dr. Nurkin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 35 procedures of colonoscopy by Dr. Nurkin, more than 56% of the clinicians it reports for that procedure.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Removal of skin lesions: 1 to 10 procedures (CMS shows small counts as a range)

Removal of tissue: 1 to 10 procedures (CMS shows small counts as a range)

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Upper gastrointestinal (GI) endoscopy for acid reflux: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 58 papers to Dr. Nurkin, published from 2012 to 2024. 2015 was the busiest year, with 7. The most frequent topics are Rectal Neoplasms, Adenocarcinoma and Esophageal Neoplasms. Dr. Nurkin has published most often in J Natl Compr Canc Netw. Dr. Nurkin's most frequent co-authors are Emmanuel M. Gabriel, MD, Steven Norbert Hochwald, MD and Moshim Kukar, MD.

Dmand AI links Dr. Nurkin to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Rectal Neoplasms and Rectal Diseases.

CMS Open Payments shows 12 general payments to Dr. Nurkin from 8 drug and device companies from 2016 to 2022. Consulting fees make up the largest share, 74% of the total. Merck Sharp & Dohme Corporation paid the most, $2,500.

Dr. Nurkin graduated from Technion-Israel Inst of Technology Faculty of Medicine in 2005.